Lupin receives USFDA approval for Generic Namenda XR Capsules

29 Sep 2016 Evaluate

Lupin has received final approval for its Memantine Hydrochloride Extended-Release Capsules, 7 mg, 14 mg, 21 mg, and 28 mg from the United States Food and Drug Administration (FDA) to market a generic version of Allergan’s Namenda XR Capsules, 7 mg, 14 mg, 21 mg, and 28 mg. Lupin's Memantine Hydrochloride Extended-Release Capsules are the AB rated generic equivalent of Allergan’s Namenda XR capsules. Memantine Hydrochloride Extended-Release Capsules, 7 mg, 14 mg, 21 mg and 28 mg are indicated for treatment of moderate to severe dementia of the Alzheimer's type. Namenda XR Capsules had US sales of $1.22 Billion.

Lupin is a pharmaceutical company and is engaged in formulation of drugs and active pharmaceutical ingredients (APIs), generics, biotechnology, novel drug discovery and development, drug delivery systems and specialty pharmaceuticals.

Lupin Share Price

2151.05 19.25 (0.90%)
30-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1595.00
Dr. Reddys Lab 1218.40
Cipla 1323.95
Zydus Lifesciences 885.20
Lupin 2151.05
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×